Researchers from the University of Illinois have demonstrated the importance of cell-type-specific targeting in the treatment of HIV. Their study, published in PNAS, is one of the first to examine the differential or cell-type specific effects of HIV latency modulation on myeloid cells, a type of immune cell made in bone marrow. 

Read More